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ABSTRACT This paper presents a study of the use of ultraviolet resonance Raman (UVRR) spectroscopic methods as a
means of elucidating aspects of drug-protein interactions. Some of the RR vibrational bands of the aromatic amino acids
tyrosine and tryptophan are sensitive to the microenvironment, and the use of UV excitation radiation allows selective
enhancement of the spectral features of the aromatic amino acids, enabling observation specifically of their change in
microenvironment upon drug binding. The three drug-protein systems investigated in this study are dihydrofolate reductase
with its inhibitor trimethoprim, gyrase with novobiocin, and catechol O-methyltransferase with dinitrocatechol. It is demon-
strated that UVRR spectroscopy has adequate sensitivity to be a useful means of detecting drug-protein interactions in those
systems for which the electronic absorption of the aromatic amino acids changes because of hydrogen bonding and/or
possible dipole-dipole and dipole-polarizability interactions with the ligand.
INTRODUCTION
A key process in the development of new drugs is elucida-
tion of the nature of the interaction between the drug mol-
ecule and the target protein. Such knowledge then makes it
possible to make systematic structural modifications of the
drug molecule to optimize the interaction. There are a
variety of techniques currently available for obtaining in-
formation about drug-protein interactions, such as the mea-
surement of kinetics and binding affinities. The two meth-
ods that have traditionally been employed to obtain
structural information of proteins and drug-protein com-
plexes are x-ray diffraction and NMR spectroscopy. Both of
these methods have disadvantages: x-ray diffraction re-
quires the preparation of a crystal, which can be time
consuming or even impossible; and NMR spectroscopy is
not easily applied to larger proteins of more than a few
hundred amino acids.
Other analytical techniques that can be applied to proteins
in solution are circular dichroism, ultraviolet absorption,
and fluorescence spectroscopy, but these all have limita-
tions. Circular dichroism is useful mainly in probing the
global structure of proteins; however, far UVCD can yield
information about protein secondary structure and near
UVCD can probe the local environment of aromatic resi-
dues, especially tryptophan (Woody and Dunker, 1996).
Although ultraviolet absorption spectroscopy is widely em-
ployed to study the phenolic hydrogen bonding (H-bonding)
of tyrosine (Tyr, Y) (Cantor and Schimmel, 1980; Dem-
chenko, 1983), this approach requires one to differentiate
the effect of Tyr H-bonding from the contribution due to all
of the other amino acids (Hildebrandt et al., 1988). With
fluorescence spectroscopy, if any tryptophan (Trp, W)
amino acids are present, they will tend to dominate the
spectrum, the signals from other residues often being com-
pletely swamped. Furthermore, it is difficult to quantita-
tively relate changes in fluorescence yields to structural
changes in proteins.
Resonance Raman (RR) spectroscopy with ultraviolet
(UV) excitation radiation has been demonstrated to be a
valuable new method for the study of biological molecules
(Spiro, 1987; Asher, 1993a,b). Recent advances in UV
lasers (Asher et al., 1993), especially the extension of laser
sources into the deep UV region, have led to the establish-
ment of UVRR spectroscopy as an active area of research.
This is evidenced by recent papers in the literature, which
document the use of UVRR in the study of the structures of
hemoglobin (Copeland et al., 1985), cytochrome c (Cope-
land and Spiro, 1985), insulin (Rava and Spiro, 1985a),
lactalbumin (Kronman et al., 1981), angiotension (Cho and
Asher, 1996), enkephalins (Takeuchi et al., 1992), human
serum albumin (including its ligand-binding modes) (Hashi-
moto et al., 1995), the extracellular domain of the human
tumor necrosis factor receptor (Tuma et al., 1995), as well
as a variety of DNA structures (Takeuchi and Sasamon,
1995). In this paper we explore the feasibility of using
UVRR spectroscopic methods to help elucidate aspects of
drug-protein interactions.
The advantages of UVRR as compared to normal Raman
spectroscopy are much improved selectivity and sensitivity.
Both advantages arise because of the large enhancement of
the cross section of Raman scattering that occurs when the
excitation laser frequency closely matches the electronic
absorption frequency of a particular chromophore. The in-
creased sensitivity of UVRR means that spectra can be
obtained at lower sample concentrations, typically on the
order of 1 mg ml1, which obviates the problem of protein
aggregation, which can occur in solutions at higher concen-
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trations. The increased selectivity means that only the res-
onantly enhanced chromophores will be featured, yielding
greatly simplified spectra of proteins. The extent and selec-
tivity of the enhancement depend on the excitation wave-
length used, and this can be exploited to good effect, be-
cause in the UV range it is the aromatic amino acids of a
protein, namely Tyr, Trp, and phenylalanine (Phe, F), which
are enhanced, and not the aliphatic amino acids. As the vast
majority of amino acids in proteins are generally aliphatic,
the efficacy of using UV excitation radiation is immediately
apparent.
It is well known that some of the vibrational bands of Tyr
and Trp are sensitive to the microenvironment. Indeed,
detailed information about the microenvironment of these
aromatic side chains can be obtained from, for example,
variations in intensity of the vibrational modes, or changes
in the intensity ratio of Fermi resonance doublets. A specific
example is the Fermi resonance doublet of Tyr, which is
sensitive to the extent of H-bonding of the phenolic hy-
droxyl (Chen et al., 1973; Siamwiza et al., 1975; Rava and
Spiro, 1985b; Johnson et al., 1986). Now drug binding is
characterized by local changes around the binding site
where H-bonds are formed or broken, and where dipole-
dipole and dipole-polarizability interactions possibly occur;
and in some cases it is characterized by additional confor-
mational changes of the protein. If the aromatic amino acids
are located near the binding site, or if they are exposed to a
different environment because of conformational changes in
the protein upon binding, it is anticipated that this will be
reflected in the UVRR spectrum. Hence these changes have
the potential both to allow qualitative detection of drug
binding, and to enable quantitative study of the nature of the
interaction between the drug and its target.
The fact that changes in environment and extent of H-
bonding can occur simultaneously and can both produce
changes in the observed UVRR spectra is a complicating
factor, because the two effects cannot be definitively de-
coupled without the knowledge of further structural infor-
mation. It is generally difficult to perform the relevant
calibration experiments required to isolate one effect from
the other, because dissolving the aromatics in a range of
solvents of varying polarity in itself creates a change in both
the environment and the extent of H-bonding. Furthermore,
it is impossible to reproduce exactly the environment of the
aromatic in the protein by dissolving it in a bulk solution.
And so, until the relationships between the different con-
tributing factors have been elucidated, interpretation of ob-
served spectral changes necessarily relies on additional
structural information.
There has been one previous UVRR study in the area of
drug-protein interaction, undertaken by Hashimoto et al.
(1995). They have studied the interaction of human serum
albumin with warfrin, ibuprofen, and palmitate, and have
obtained evidence for a direct interaction between warfrin
and the Trp at position 214 (Trp214), and between ibuprofen
and the phenolic hydroxyl of Tyr411. Human serum albumin
is readily available, and these experiments were performed
using 2-ml samples at albumin concentrations of 120 mM.
The sample was recirculated with a spinning quartz cell.
Three different drug-protein systems were chosen for the
work reported here, all of which are of current pharmaceu-
tical interest. For some of the systems there is additional
structural information from other techniques (particularly
from x-ray diffraction data) with which to compare the
UVRR data. The drug-protein systems used in our study are
dihydrofolate reductase (DHFR) with its inhibitor tri-
methoprim (TMP), gyrase with novobiocin, and catechol
O-methyltransferase (COMT) with dinitrocatechol (DNC).
EXPERIMENTAL
Materials
All of the samples and drugs were generous gifts from F. Hoffman-La
Roche and were used as supplied. Each of the three systems is described in
turn.
DHFR/TMP
The DHFR used in this study was isolated from Staphylococcus aureus,
and is an 18.1-kDa enzyme of 159 residues (including 2 Trp, 3 Tyr, and 11
Phe); its amino acid sequence is given in Table 1. The enzyme was
overproduced in Escherichia coli; the recombinant protein was isolated and
purified to homogeneity as described by Dale et al. (1994). In addition to
the wild type, the mutant DHFR(F98Y), with point mutation F98Y, has
also been isolated; this mutant shows resistance to TMP. The TMP was
purchased from Sigma; its structure is depicted in Fig. 1 a. The DHFR and
DHFR/TMP complex samples were made up to concentrations of1.3 mg
ml1 in phosphate buffer.
Gyrase/novobiocin
F. Hoffmann-La Roche have isolated a 25.9-kDa fragment of the B subunit
of gyrase, which incorporates the binding pocket for the coumarin drug
novobiocin. The gyrase was prepared by the method described by Lewis et
al. (1994, and references therein). This 233-amino-acid fragment has a total
of 2 Trp, 11 Tyr, and 5 Phe; the complete amino acid sequence is listed in
Table 2. The x-ray crystal structure of the S. aureus protein fragment has
been solved by F. Hoffmann-La Roche (unpublished results) and has been
found to be comparable to the E. coli structure (Ali et al., 1993), especially
with respect to the novobiocin binding pocket. The novobiocin was pur-
chased from Fluka; its structure is shown in Fig. 1 b. UVRR spectra of
TABLE 1 Amino acid sequence of S. aureus dehydrofolate reductase
1 TLSILVAHDL QRVIGFENQL PWHLPNDLKH VKKLSTGHTL VMGRKTFESI
51 GKPLPNRRNV VLTSDTSFNV EGVDVIHSIE DIYQLPGHVF IFGGQTLFEE
101 MIDKVDDMYI TVIEGKFRGD TFFPPYTFED WEVASSVEGK LDEKNTIPHT
151 FLHLIRKKV
The mutant has the point mutation F98Y.
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gyrase were measured using samples of concentration1.0 mg ml1 made
up in Tris buffer at pH 8.5.
COMT/DNC
The rat liver COMT used in this work is a 24.7-kDa protein of 221 residues
(including 2 Trp and 10 Tyr) (see Table 3 for the amino acid sequence).
The preparation of COMT has been described by Vilbois et al. (1994). The
DNC was synthesized by F. Hoffmann-La Roche, and the sinefungine was
purchased from Sigma; their structures are shown in Fig. 1, c and d,
respectively. UVRR spectra were recorded for COMT made up in Tris
buffer (pH 7.5) at concentrations of 2.7 mg ml1, and for COMT
complexes with sinefungine and DNC at equivalent concentrations.
Method
The UVRR apparatus has previously been described in detail (Couling et
al., 1997), and only the salient features are discussed here. Continuous-
wave UV radiation of wavelength 244 nm is obtained from an intracavity
frequency-doubled argon-ion laser (Spectra-Physics model 2020). Optics
are UV optimized throughout, and collecting optics consist of a parabolic
mirror and a Dilor model XY triple-grating spectrometer with a double
foremonochromator. Detection is by means of a Dilor multichannel diode
array. All samples were held at 25°C in a 100-l glass cuvette with a
sapphire window, and were continuously stirred to minimize photodegra-
dation. The sapphire has only one sharp RR vibrational peak, which is near
750 cm1 (Watson et al., 1981). The power of the beam at the cuvette was
9 mW. Whenever a buffer was used, a background measurement of neat
buffer was recorded to verify that its spectrum did not interfere with the
spectra from the protein-ligand systems. Spectra were recorded with the
spectrometer entrance slit set at 80 m, which corresponds to a spectral
resolution of 8.6 cm1. Adequate signal-to-noise ratios were obtained by
accumulating 30 spectra of 30-s duration each, together with dark background
subtraction. Data collection was performed with an IBM-compatible personal
computer; the spectra were subsequently analyzed and manipulated using the
GRAMS/386 scientific package of Galactic Industries Corporation.
The solutions in this study have not been spiked with an internal marker,
because the salts commonly used for this purpose are not Raman enhanced,
which means that they have to be used at high concentrations. Extensive
experiments would have to be undertaken to see whether, and if so then to
what extent, the internal marker affects a protein’s structure. A consequence of
the absence of an internal standard is that absolute changes in intensity of
vibrational bands could not be quantitatively measured from spectra.
To obtain the various peak ratios quoted in the Results and Discussion
that follow, the baseline and peak heights were measured using GRAMS.
The major contribution to the uncertainty in the ratios arises from the
estimate of the baseline position. The quoted uncertainty limits were
obtained by calculating these ratios from the highest and lowest possible
baselines, whereas the numerical values were calculated using the average
of these extremes. When the spectra were remeasured, the ratios were
generally found to be within these error margins. Where successive spectra
were recorded to allow spectral subtractions (via GRAMS) to reveal small
changes in vibrational features, care was taken to ensure reproducibility of
experimental conditions. If, for example, the UVRR spectrum of a protein
was to be subtracted from its drug-protein complex, care was taken to
maintain equal solution concentrations.
RESULTS AND DISCUSSION
The UVRR spectra of the various proteins and drug-protein
complexes investigated in this study will be systematically
presented and discussed in this section. Each of the three
FIGURE 1 Chemical structures of (a) trimethoprim (TMP), (b) novobiocin, (c) dinitrocatechol (DNC), and (d) sinefungine.
TABLE 2 Amino acid sequence of the 25.9-kDa fragment of the B subunit of S. aureus gyrase
1 VTALSDVNNT DNYGAGQIQV LEGLEAVRKR PGMYIGSTSE RGLHHLVWEI
51 VDNSIDEALA GYANQIEVVI EKDNWIKVTD NGRGIPVDIQ EKMGRPAVEV
101 ILTVLHAGGK FGGGGYKVSG GLHGVGSSVV NALSQDLEVY VHRNETIYHQ
151 AYKKGVPQFD LKEVGTTDKT GTVIRFKADG EIPTETTVYN YETLQQRIRE
201 LAFLNKGIQI TLRDERDEEN VREDSYHYEG GIK
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systems will be examined separately, but it is perhaps best
to begin with a general discussion of the interpretation of
UVRR spectra.
As has already been mentioned, a number of Tyr and Trp
vibrational bands show sensitivity to their environment. The
well-known Tyr Fermi resonance doublet, which is seen at
830/850 cm1, has been ascribed to the interaction of the 1
ring-breathing mode with the overtone of the out-of-plane
deformation mode 16a (Siamwiza et al., 1975; Rava and
Spiro, 1985b). All work published to date indicates that the
major factor affecting this Tyr doublet ratio is the extent of
H-bonding of the phenolic hydroxyl (-OH) (Chen et al.,
1973; Siamwiza et al., 1975; Rava and Spiro, 1985b; John-
son et al., 1986), which can serve as either a proton donor
or an acceptor, or as both simultaneously (Baker and Hub-
bard, 1984). A certain correlation exists between the inten-
sity ratio I850/I830 of the doublet peaks and the nature of the
H-bonding. In general, the ratio is small for a Tyr whose
-OH acts as a hydrogen donor, and is conversely large for a
Tyr whose -OH acts as a hydrogen acceptor (Harada and
Takeuchi, 1986b). In a previous study we have determined
I850/I830 for Tyr by using the model compound p-cresol (the
vibrational pattern of which is similar to that of Tyr) dis-
solved in a range of solvents of varying polarity and known
H-bond enthalpies of formation (Couling et al., 1997).
These UVRR spectra were obtained by using an excitation
radiation of wavelength 244 nm. For those Tyr amino acids
in a protein that are exposed to aqueous solution, hence
acting as weak proton donors or acceptors, one expects
I850/I830  1, whereas for those Tyr that are buried in
hydrophobic pockets, a ratio I850/I830  1 is expected
(Siamwiza et al., 1975). In proteins the tyrosyl residue is
known to exist as a strong hydrogen donor to groups such as
CO2
 and NH2, a medium-to-weak hydrogen donor and/or
acceptor, or a strong hydrogen acceptor from groups like
NH3
 and CO2H (Harada and Takeuchi, 1986b).
Among the tryptophyl bands in the Raman spectra of
proteins, the region around 1350 cm1, which comprises
two or three peaks, has been found to be sensitive to its
environment (Chen et al., 1973, 1974; Harada et al., 1986).
The relationship between the intensity ratio of the Fermi
resonance doublet peaks at 1340 cm1 and 1360 cm1,
I1360/I1340, has been studied for indole, which is a model
compound for Trp, having the same chromophore. I1360/
I1340 for a Trp residue in a protein whose environment is
similar to that of indole in solution was found to be less than
1 if exposed to aqueous solution, 1 if in contact with
aromatic amino acid residues, and greater than 1 if in
contact with aliphatic side chains (Harada and Takeuchi,
1986). However, care must be taken in applying the rela-
tionship of the Fermi resonance doublet obtained from
off-resonance Raman studies to resonance Raman spectra
(Rava and Spiro, 1985a). We nevertheless expect that the
general trend of the spectral change and its interpretation to
hold equally in the resonance Raman case (Harada et al.,
1986). A complete assignment of the Trp bands at 1350
cm1 and their interpretation are not possible at present for
any but the simplest of systems. For example, the behavior
of this doublet in UVRR spectra of horse cytochrome c
(Copeland and Spiro, 1985) cannot be explained by the
indole study. A quantitative analysis is further complicated
by the possible overlap of the CH bending band that occurs
around 1320–1340 cm1.
There is evidence from previous work that the UV Raman
cross section for 244-nm excitation radiation increases for
Tyr and Trp going from a hydrophilic to a hydrophobic
environment (Hashimoto et al., 1995). This can be ex-
plained by a red shift in the electronic absorption as a result
of dipole-dipole, dipole-polarization, and/or H-bonding in-
teractions (Cho and Asher, 1996). By the use of an internal
intensity standard, the enhancement in intensity has been
estimated to be a factor of 2 to 4 at this wavelength (Hashi-
moto et al., 1995). Although it was not possible to spike our
samples with an internal marker in this study, we neverthe-
less anticipate that the signals from these aromatic amino
acids should dominate the UVRR spectra.
The results for the DHFR/TMP, gyrase/novobiocin, and
COMT/DNC systems are now discussed in this order.
The dehydrofolate
reductase/trimethoprim system
DHFR, which catalyzes the NADPH-dependent reduction
of 7,8-dihydrofolate to 5,6,7,8-tetrahydrofolate, is an intra-
cellular receptor for a number of drug molecules. Inhibition
of this DHFR-catalyzed reaction attenuates the biosynthesis
of certain nucleotides and amino acids. Some drugs display
selective inhibition of DHFR from different species; for
example, the folate analog TMP binds 105-fold less tightly
to mammalian DHFR than it does to bacterial DHFR
(Champness et al., 1986; Stryer, 1995), making it a potent
antibacterial drug. A point mutation on bacterial DHFR,
F98Y, has been shown to be responsible for determining the
TMP resistance (Dale et al., 1997).
A large amount of kinetic and spectroscopic evidence
from solution studies has pointed to the mechanistic impor-
tance of conformational changes of DHFR upon ligand
TABLE 3 Amino acid sequence of rat liver catechol-O-methyltransferase
1 MGDTKEQRIL RYVQQNAKPG DPQSVLEAID TYCTQKEWAM NVGDAKGQIM
51 DAVIREYSPS LVLELGAYCG YSAVRMARLL QPGARLLTME MNPDYAAITQ
101 QMLNFAGLQD KVTILNGASQ DLIPQLKKKY DVDTLDMVFL DHWKDRYLPD
151 TLLLEKCGLL RKGTVLLADN VIVPGTPDFL AYVRGSSSFE CTHYSSYLEY
201 MKVVDGLEKA IYQGPSSPDK S
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binding (Kraut et al., 1987). DHFR has three Tyr and two
Trp residues that are close to the binding site, and which
should prove to be good UVRR spectroscopic indicators of
drug binding. Trp22 is highly conserved in DHFR proteins
produced from various strains and is directly involved in the
TMP binding. It is this Trp residue that forms, via the NH
group, an H-bond with a water molecule in the binding
pocket. The water molecule, in turn, forms H-bonds with
Asp27, which itself interacts with the 2 amino group and the
NH bond of TMP. This structural feature is present in all
known DHFR/TMP bindings (W. Huber, F. Hoffmann-La
Roche, private communication).
Because TMP is not resonantly enhanced at our excita-
tion wavelength of 244 nm, it was not possible in this study
to use UVRR spectroscopy to detect structural changes in
the drug upon binding.
The UVRR spectra of DHFR and the DHFR/TMP com-
plex are shown together in Fig. 2, a and b, respectively. A
number of vibrational bands can be identified (mode num-
bering follows that of Rava and Spiro, 1985b) in both
spectra, among which is the strong peak at 1619 cm1,
which is due to the 8a vibrations of Trp at 1622 cm
1 and
Tyr at 1617 cm1. There is also a contribution from the
amide I band at 1654 cm1. The Trp doublet peaks occur at
1354 cm1 and 1340 cm1. Weak bands at 1208 cm1 and
1180 cm1 arise from the C6H5-C stretching of phenylala-
nine and the Tyr 9a mode, respectively. The peak occurring
around 1000 cm1 is the Phe 1 ring-breathing mode.
Because there are no resonantly enhanced spectral fea-
tures of TMP at our experimental wavelength, only changes
in the UVRR spectrum of the enzyme can be observed upon
binding of the drug. In particular, the environment-sensitive
ratio I1356/I1340 of the Trp doublet at1350 cm1 is seen to
change from 1.02  0.05 for DHFR (see Fig. 2 a) to 1.3 
0.1 for the DHFR:TMP (1:1) complex (see Fig. 2 b). A Trp
residue is located next to the binding pocket, and it is
expected that its environment will change significantly once
the drug binds. It is not possible from our measurements of
I1356/I1340 to make quantitative deductions about the exact
environment of the Trp residues, because the doublet ratio
has thus far only been studied for simple proteins and model
compounds such as indole (Harada et al., 1986). An impor-
tant observation is that no changes in this doublet ratio were
discernible in the UVRR spectra of mutant DHFR (F98Y)
and DHFR(F98Y):TMP (1:1) complex. The RR spectra
indicate that wild-type DHFR undergoes binding of TMP,
leading to substantial environmental and/or structural
changes, whereas the mutant, as expected, does not bind
TMP. The Tyr doublet at 850/830 cm1 could not be seen
in any of these spectra.
The gyrase/novobiocin system
The bacterial enzyme DNA gyrase is a type II topoisomer-
ase that catalyzes the introduction of negative supercoils
into closed circular DNA (Gellert et al., 1976a; Wang, 1985;
Reece and Maxwell, 1991; Ali et al., 1993). The enzyme
from E. coli consists of two proteins, A and B, of molecular
masses 97 kDa and 90 kDa, respectively. The active enzyme
is an A2B2 heterodimeric complex (Ali et al., 1993). A great
deal of attention has been focused on the enzyme’s struc-
ture, mechanism of action, and interaction with antibacterial
agents. DNA gyrase is the target of two groups of antibac-
terial agents, the quinolines and the coumarins, both of
which inhibit the DNA supercoiling reaction (Gellert et al.,
1976b; Lewis et al., 1996). The coumarins, such as novo-
biocin, inhibit the ATPase reaction of gyrase and bind to the
B subunit (Ali et al., 1993). F. Hoffman-La Roche have
isolated a 25.9-kDa fragment of the S. aureus B subunit,
which incorporates the binding pocket for novobiocin. This
fragment contains 2 Trp, 11 Tyr, and 5 Phe, and its crystal
structure (W. Huber, F. Hoffmann-La Roche, unbublished
results) closely resembles that of the E. coli fragment
(Lewis et al., 1996).
Novobiocin has a highly flexible molecular frame, and it
is expected that the drug molecule is forced into a preferred
conformation when it binds to the protein. This conforma-
tional change should be reflected in the vibrational spectrum
of novobiocin. The drug molecule has extended ring con-
jugation, and is itself resonantly enhanced at 244 nm. The
UVRR spectra of the enzyme and the novobiocin overlap,
and so to distinguish between spectral changes due to the
enzyme and those arising from the drug, the novobiocin
spectrum had to be subtracted from spectra of the drug-
target complex by the use of GRAMS. Similarly, the gyrase
spectrum was subtracted when the effect on novobiocin
upon binding was to be examined.
The spectrum of unbound gyrase can be seen in Fig. 3 a,
and the spectrum of the gyrase:novobiocin (1:1) complex is
shown in Fig. 3 c. The binding pocket of gyrase contains
neither Tyr nor Trp residues, the nearest Tyr being 10 Å
FIGURE 2 UV Raman spectra of the DHFR/TMP system with (a) free
DHFR and (b) DHFR:TMP (1:1). For clarity, the tryptophan doublet
regions are shown enlarged.
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away, and the nearest Trp20 Å away from the binding site
(W. Huber, F. Hoffmann-La Roche, private communica-
tion). Nevertheless, both the Trp doublet at 1350 cm1
and the Tyr Fermi resonance doublet at 840 cm1 are
observed to undergo changes in their intensity ratios when
the drug binds. A frequency upshift of the Trp 3 band from
1555 cm1 (see Fig. 3 a) to 1559 cm1 (see Fig. 3 c) upon
complexation corresponds to a change in the torsion angle
2,1 for the C2-C3-C-C linkage from 115° to over 120°
(Miura et al., 1989). The Tyr Fermi resonance doublet for
free gyrase has an intensity ratio I850/I830  1.0  0.2,
whereas the gyrase:novobiocin (1:1) complex has an inten-
sity ratio I850/I830  1.7  0.1. The Trp doublet changes its
ratio from I1357/I1340  1.36  0.08 to I1357/I1338  0.94 
0.02 upon binding of the drug. A new band that appears at
1272 cm1 is a novobiocin vibrational feature. The 8b
vibration of Tyr occurs at 1618 cm1 for the free enzyme,
but undergoes a frequency downshift to 1613 cm1 when
the novobiocin binds. The relatively weak peak around
1175 cm1 in the spectra of gyrase and the gyrase:novo-
biocin (1:1) complex is the Tyr 9a band.
The frequency downshifts of the Tyr 9a vibration from
1178 cm1 to 1175 cm1 and the 8b mode from 1618 cm
1
to 1613 cm1, when novobiocin binds gyrase, together with
the increase in the strength of the Tyr 9a mode, are con-
sistent with the changes observed in the tyrosine and tryp-
tophan doublet ratios. The change would correspond to an
alteration of the tyrosine and tryptophan local environment
from hydrophobic to hydrophilic. However, because these
amino acids are not close to the binding pocket, the change
in environment has to be ascribed to dipole-dipole and
dipole-polarizability interactions between the novobiocin
and the aromatic amino acids (Kamlet et al., 1981; Cho and
Asher, 1996).
In addition to the substantial changes that occur in the
UVRR spectrum of gyrase when novobiocin binds, the
spectrum of the drug itself undergoes several changes.
When the gyrase-subtracted UVRR spectrum of the bound
drug, given in Fig. 3 d, is compared with the spectrum of
free novobiocin at the same concentration (0.5 mg in 0.05
ml Tris buffer; Fig. 3 b), it is evident that the spectrum of
the bound drug features both shifted bands and new bands.
The coumarin-hydroxybenzoate part of novobiocin is struc-
turally similar to warfarin (chemical structure not shown). A
UVRR study of warfarin (Hashimoto et al., 1995) ascribed
most of the observed bands at 1603, 1511, 1485, 1448,
1419, and 1333 cm1 to the hydroxycoumarin part of the
drug.
FIGURE 3 UV Raman spectra of the gyrase/novobiocin system with (a) free gyrase, (b) free novobiocin, (c) gyrase:novobiocin (1:1) complex, (d)
gyrase:novobiocin (1:1) complex minus free gyrase.
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The spectrum of the gyrase:novobiocin (1:1) complex
minus the spectrum of gyrase contains changes due to both
the novobiocin and the gyrase. The spectral changes due to
gyrase are marked (*) in Fig. 3 d. Similar spectral features
were observed by Takeuchi and Sasamon (1995) when
binding warfarin to human serum albumin. These features
were assigned to the hydroxycoumarin part of the drug,
although a detailed vibrational assignment has not been
performed. An increase in the intensity of the bands at 1605
cm1 and 1560 cm1, and a decrease in the intensity of
those at 1484 cm1 and 1419 cm1 was observed in the
UVRR spectra once warfarin bound to the albumin, and
these features were attributed to the binding of warfarin to
a hydrophobic region. In contrast, we observe substantial
changes in the novobiocin spectrum that differ from the
changes we observe for novobiocin in a nonaqueous solvent
or as a function of pH, as seen in Fig. 4. The evidence
strongly suggests that novobiocin undergoes substantial
structural changes upon binding to gyrase.
Because the crystal structures of the Apo enzyme and that
of the complex were found to be similar (W. Huber, F.
Hoffmann-La Roche, private communication), we must
conclude that the spectral changes in the Tyr and Trp
observed upon ligand binding are associated with dipole-
dipole and dipole-polarizability interactions (Kamlet et al.,
1981; Cho and Asher, 1996) between the novobiocin chro-
mophore and the aromatic amino acids.
It should be noted that Lewis et al. (1996) do not state
whether changes in the novobiocin structure upon binding
were observed.
The catechol O-methyltransferase/
dinitrocatechol system
Catechol O-methyltransferase (COMT) is an enzyme dis-
tributed within the brain and its peripheral organs. It is
important for the central nervous system, as it metabolizes
catecholamine neurotransmitters such as dopamine. The
enzyme catalyzes the transfer of the methyl group from
S-adenosyl-L-methionine (AdoMet) to catechol substrates
such as 3,5-dinitrocatechol (DNC) (Vidgren et al., 1994).
This transfer occurs in a ternary complex of the protein with
the coenzyme (AdoMet) and the catechol derivative. The
formation of the ternary complex is dependent on the pres-
ence of Mg2, this ion being complexed by amino acids
such as Asp and Asn in the binding pocket of the cofactor.
The binding site for DNC is in the shallow groove on the
surface of the protein. No protruding part of the protein
encloses the inhibitor. Sinefungine differs only slightly
from AdoMet, and acts as the substrate in this study.
The rat liver COMT used in this study has 221 amino
acids and a molecular mass of 24.7 kDa. The crystal struc-
tures of both the COMT and the ternary complex have been
solved (Vidgren et al., 1994), and it is known that the
complex formation causes significant conformational
changes on the protein. One of the protein’s two Trp resi-
dues, namely Trp143, is located near the binding site, and is
involved in the conformational change. Trp143 has a favor-
able van der Waals interaction with the 3-nitro group of the
inhibitor, and so it is anticipated that the binding event
should be detectable in the vibrational spectrum of Trp. The
other Trp, Trp38, is located edge to face with the planar
structure of DNC, allowing for an ideal hydrophobic contact
(Vidgren et al., 1994).
Because the UVRR spectrum of sinefungine has peaks in
the Tyr region of interest, spectral subtractions of sinefun-
gine are required if changes in the UVRR spectra of COMT
are to be discerned upon binding of this ligand. The DNC
does not show any RR spectral features at our excitation
wavelength.
The UVRR spectra for this system are displayed in Fig. 5
and are now discussed in detail.
To compare the various spectra and to quantify possible
changes, we quote peak ratios with their respective uncer-
tainties in the region of the Trp doublet. In the spectrum of
pure COMT (see Fig. 5 a), the peaks in this doublet region
occur at 1370 cm1, 1361 cm1, 1345 cm1, and 1334
cm1, the latter being the dominant peak. The peak intensity
ratio, I1361/I1335  0.66  0.04, was measured with
GRAMS.
For the COMT:DNC (1:1) mixture, the 1327 cm1 peak
still dominates, with I1366/I1332  0.62  0.06. In the
signal-to-noise resolution no other spectral features occur,
FIGURE 4 UV Raman spectra of novobiocin (a) at pH 7, (b) at pH 11,
and (c) in methanol.
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indicating that no major structural changes have taken place.
And indeed, the subtraction of the COMT spectrum from
that of the COMT/DNC complex is featureless. However,
the spectrum of the COMT:sinefungine (1:1) system indi-
cates structural changes of COMT upon subtraction of the
sinefungine spectrum. The 1370 cm1 Trp peak becomes
prominent, whereas the 1340 cm1 peak is reduced in
intensity, yielding I1370/I1340  0.93  0.05.
In the COMT:DNC:sinefungine (1:1:1) system (added in
this order), after subtraction of the sinefungine, the spec-
trum resembles that of pure COMT, which is reflected in the
ratio I1370/I1340  0.62  0.11. If one infers from this that
the structure of COMT has not changed, then this is indic-
ative of DNC’s role as an inhibitor. Contrast this with the
COMT:Sinefungine:DNC (1:1:1) system (added in this or-
der), which after subtraction of the sinefungine, yields a
spectrum bearing a close resemblance to the COMT:sine-
fungine complex, the ratio I1364/I1353 being 0.99  0.08.
Because sinefungine has already bound, the DNC, which is
a competitive inhibitor, can no longer inhibit sinefungine
from binding. We would like to stress that the only differ-
ence between the COMT:DNC:sinefungine and the COMT:
sinefungine:DNC spectra is the order in which the ligands
were added. It follows that any spurious features that may
arise because of peak alignment, subtraction, and ratioing
are ruled out, and hence give us confidence in our analysis
of the COMT system.
The crystal structure of the COMT/AdoMet complex has
been determined (Vidgren et al., 1994), and Trp143 has been
shown to have a favorable edge-to-face interaction with
AdoMet. We expect Trp143 to display similar behavior
when COMT binds sinefungine. From this crystal structure
it is clear that the binding of the planar 3,5-dinitrocatechol
takes place in a shallow groove on the outside of the protein,
and involves an edge-to-face interaction with Trp38 that
allows for a hydrophobic contact (Vidgren et al., 1994).
Now the observed Trp doublet is the intensity-averaged
signal from both Trp residues. The doublet ratio changes are
more pronounced when COMT binds sinefungine than
when it binds DNC. For free COMT, the ratio suggests that
both Trp residues are in an aqueous environment. Once
DNC has bound, a small change in the ratio is observed
because of the edge-to-face interaction, although the envi-
ronment is still largely aqueous. In contrast, the binding of
singefungine results in a larger ratio change, which is prob-
ably due both to an intensity enhancement of the signal from
Trp143, so that it makes a relatively larger contribution to the
observed signal of the two Trp residues, and to an interac-
tion with singefungine, which results in a hydrophobic
environment.
FIGURE 5 UV Raman spectra of the COMT system with (a) free COMT, (b) sinefungine, (c) COMT:DNC (1:1) complex, (d) COMT:sinefungine (1:1)
minus sinefungine, (e) COMT:DNC:sinefungine minus sinefungine, and (f) COMT:sinefungine:DNC minus sinefugine.
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CONCLUSION
We have demonstrated that UVRR spectroscopy has ade-
quate sensitivity to be a useful means of detecting drug
binding. In this study we see that the technique indicates
that DHFR binds TMP, whereas the mutant DHFR(F98Y)
does not. It also indicates that the environment of one or
more Trp residues change from being in contact with an
aliphatic side chain to becoming in contact with an aromatic
side chain. The intensity enhancement that occurs when going
from a hydrophilic to a hydrophobic environment means that
the observed change in the Trp Fermi resonance doublet ratio
arises from the Trp located in the binding pocket, which comes
into contact with the aromatic TMP upon binding. Even in the
gyrase/novobiocin system, where no Tyr or Trp residues are
located directly in the binding pocket, we have been able to
detect changes in both the Trp and the Tyr Fermi resonance
doublet ratios, which are clear indicators of binding. The
observed spectral changes have been attributed to dipole-di-
pole and dipole-polarizability interactions. UV resonance en-
hancement of the novobiocin means that we have been able to
show that the drug itself undergoes conformational changes
upon binding. Finally, UVRR spectroscopy is able to correctly
identify the role of DNC as an inhibitor in the COMT system,
in which sinefungine, being similar to AdoMet, acts as the
substrate. The changes were monitored using the doublet ratio
of two Trp residues: one located in the shallow groove that
binds DNC, and the other in the pocket where sinefungine
binds. The changes indicate that the Trp residues are initially
exposed to the aqueous solvent, and subsequently find them-
selves in a hydrophobic environment.
The environment inside a protein is unique, and it is not
possible to undertake calibration experiments by simply
placing an aromatic amino acid in different solvents to alter
the extent of H-bonding or hydrophobicity. This problem
makes definitive structural interpretation of the observed
changes in the doublets difficult, and the analysis necessar-
ily still relies on x-ray diffraction data. However, the UVRR
technique has the strength that it can provide information
about Tyr residues in the protein that would not be available
from fluorescence spectroscopy data, where the fluores-
cence is dominated by tryptophans. It has the additional
advantage over fluorescence spectroscopy methods, where
the signal can be dominated by a particular Trp residue
because of differences in quenching efficiency. UVRR
spectroscopy would therefore be complementary to fluores-
cence techniques, and in fact both measurements could be
performed in the same experiment. This is clearly a future
direction that could be profitably explored. Further possi-
bilities of future experiments include following doublet
band ratios as a function of drug concentration to deduce
binding constants. Whenever the drug is resonantly en-
hanced, such as for novobiocin, the spectral changes in the
drug upon complexation can be used to investigate compet-
itive binding. Our present study on COMT indicates that it
would also be possible to observe agonist-antagonist inter-
actions with the protein.
At present there is scope to improve our instrumentation,
to make it possible to obtain spectra at even lower concen-
trations, or from smaller volumes, by improved throughput
of the Raman spectrometer. This would also decrease the
integration time. Further work is clearly required, but this
study conclusively indicates that UVRR spectroscopy has
potential as a new means of probing protein-drug interac-
tions, and shows promise as an investigative technique in
drug development.
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